Search research articles
Contact Us
Filters
Showing results (481-490 of 587) with videos related to
Page
of 59
Sort By:
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature
|
October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine
|
October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine
|
October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine
|
October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
The Lancet. Oncology
|
July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
Rodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2018
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome
Marie-Andrée Forget, Cara Haymaker, Kenneth R Hess, et al.
Annals of Surgical Oncology
|
January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
The New England Journal of Medicine
|
March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P Patel, Megan Othus, Yuanbin Chen, et al.
Nature
|
June 15, 2022
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Christopher P Vellano, Michael G White, Miles C Andrews, et al.
Page
of 59
Search research articles
Search
Showing results (481-490 of 587) with videos related to
Sort By:
Page
of 59
The Lancet. Oncology
|
January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.
Nature
|
October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanoma
Rodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.
Nature Medicine
|
October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine
|
October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
Nature Medicine
|
October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.
The Lancet. Oncology
|
July 4, 2019
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
Rodabe N Amaria, Alexander M Menzies, Elizabeth M Burton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 1, 2018
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome
Marie-Andrée Forget, Cara Haymaker, Kenneth R Hess, et al.
Annals of Surgical Oncology
|
January 28, 2022
Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)
Alexander C J van Akkooi, Tina J Hieken, Elizabeth M Burton, et al.
The New England Journal of Medicine
|
March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma
Sapna P Patel, Megan Othus, Yuanbin Chen, et al.
Nature
|
June 15, 2022
Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Christopher P Vellano, Michael G White, Miles C Andrews, et al.
Page
of 59